Zydus Lifesciences Launches Diasens and GlucoLive CGM Devices for AI-Enabled Diabetes Monitoring

The company said the devices form part of its companion diagnostics portfolio and are designed to monitor glucose levels continuously while integrating with a digital care ecosystem for patients, caregivers, and healthcare providers.

Zydus Lifesciences Limited has introduced Diasens and GlucoLive, two continuous glucose monitoring (CGM) devices aimed at supporting diabetes management through artificial intelligence-driven insights and real-time connectivity with clinicians.

The company said the devices form part of its companion diagnostics portfolio and are designed to monitor glucose levels continuously while integrating with a digital care ecosystem for patients, caregivers, and healthcare providers.

Zydus has partnered with Digicare Health Solutions Private Limited (TatvaCare) to provide access to the GoodFlip platform, a mobile application that supports AI-based report analysis, diet and exercise coaching, teleconsultations, diagnostic test booking and digital medical record storage.

Sharvil Patel, Managing Director of Zydus Lifesciences Limited, said the launch expands the company’s focus on companion diagnostics for chronic disease management.

“The launch of Diasens and GlucoLive strengthens our companion diagnostics portfolio for chronic disease management. These CGMs powered by AI technology will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control,” Patel said.

According to the Indian Council of Medical Research INDIAB study published in The Lancet Diabetes & Endocrinology, India has more than 101 million adults living with diabetes, representing the second-largest diabetes population globally. The study also estimates that about 136 million people in the country are in the pre-diabetic stage.

Diabetes is also a major contributor to Chronic Kidney Disease in India, with approximately 25–40 percent of CKD patients having a history of diabetes. The company noted that nearly 200,000 patients require kidney transplants and around 25,000 require liver transplants annually, with some patients developing diabetes following immunosuppressive therapy.

Zydus stated that glucose monitoring in India largely remains episodic, typically relying on finger-prick tests or periodic HbA1c laboratory tests conducted every three to six months.

The newly launched CGM devices automatically transmit glucose readings to a patient’s smartphone every three minutes without requiring manual scanning. Existing CGM systems often depend on near-field communication technology that requires users to scan sensors to retrieve readings.

The company said Diasens and GlucoLive continuously capture glucose data, including overnight readings and emergency situations. Through the GoodFlip application, AI-based analytics can identify glucose trends, flag hypo- and hyperglycemic episodes, correlate fluctuations with food intake or activity, and generate insights for users.

A clinician dashboard within the platform will allow remote monitoring and support treatment adjustments based on continuous data tracking.

Stay tuned for more such updates on Digital Health News